tan attila, m.d. and timothy r. koch, m.d. · physiological basis for gastric smooth-muscle ......
TRANSCRIPT
427
23 Pathophysiology and Management of Diabetic Gastropathy
Tan Attila, M.D. and Timothy R. Koch, M.D.
CONTENTS
I. Introduction................................................................................................428
II. Physiological Basis for Gastric Smooth-Muscle Activity ........................428
III. Pathophysiology of Diabetic Gastropathy.................................................429
IV. Symptoms of Diabetic Gastropathy ..........................................................431
V. Perspectives on Evaluation of Gastric Emptying......................................431
VI. Contemporary Methods for Evaluation of Gastric Emptying ..................432
A. Upper-Gastrointestinal X-Ray Series................................................433
B. Scintigraphic Assessment of Gastric Emptying ...............................433
C. Tracer Methods..................................................................................433
D. Ultrasonography ................................................................................434
E. Magnetic Resonance Imaging (MRI) ...............................................434
F. Electrogastrography (EGG)...............................................................434
VII. Evaluation of Patients with Suspected Diabetic Gastropathy ..................435
VIII. Treatment Strategies in Diabetic Gastropathy ..........................................436
A. Introduction .......................................................................................436
B. Dietary and Supportive Therapy .......................................................436
C. Optimizing Glycemic Control...........................................................436
D. Metoclopramide.................................................................................437
E. Erythromycin.....................................................................................437
F. Cisapride............................................................................................437
G. Domperidone .....................................................................................438
H. Tegaserod...........................................................................................438
I. Refractory Gastropathy .....................................................................438
IX. Future Studies ............................................................................................439
References..............................................................................................................439
428 Nutrition and Diabetes: Pathophysiology and Management
I. INTRODUCTION
Diabetes mellitus, with an estimated prevalence of 3 percent to 10 percent of the
population, is the fourth leading cause of death in the U.S. This disease complex
can affect almost every organ system, including the gastrointestinal tract. Patho-
physiologic changes involving the gut can be related to either acute hyperglycemia
or chronic changes resulting from neuropathic or myopathic processes. This chap-
ter will focus on the pathophysiology, diagnosis, and management of diabetic
gastropathy.
The clinical presentation of diabetic gastropathy is not specific and may overlap
with both structural disorders and functional dyspepsia. Nausea, vomiting, bloating,
early satiety, postprandial fullness, and upper-abdominal discomfort are the most
common presenting symptoms.1 Abdominal pain, which is likely due to gastric
distension or retension, may be an important component of the overall symptoma-
tology.2 Interestingly, symptoms do not correlate well with gastric-emptying rate;
therefore, an improvement in the gastric-emptying rate does not always result in
symptomatic improvement, or vice versa.
II. PHYSIOLOGICAL BASIS FOR GASTRIC SMOOTH-MUSCLE ACTIVITY
Gastrointestinal-contractile activity is regulated by smooth-muscle electromechani-
cal properties.3 Gastric smooth muscle, similar to other smooth muscle, is charac-
terized by a voltage-tension curve. In this relationship, depolarization of smooth-
muscle cell membrane results in increased smooth-muscle tonic contraction. Slow
waves, the basic gastric smooth-muscle electrical event, are periodic, regular depo-
larizations from the cell’s resting membrane potential.4 A slow wave follows a set
sequence during changes in resting membrane potential: initially, a rapid upstroke
depolarization, a partial repolarization, a sustained plateau potential, and then com-
plete repolarization to the resting membrane potential. This chain of events is largely
the result of activation and deactivation of calcium channels and calcium-dependent
potassium channels. Only slow waves exceeding a threshold depolarization will
result in an action potential leading to smooth-muscle contraction.
The basic rhythmic activity of gastric smooth-muscle cells is thought to originate
from the interstitial cells of Cajal, which are located in the greater curvature at the
junction of proximal and distal stomach.5–8 Interstitial cells of Cajal are found
throughout the gastrointestinal tract. Both extrinsic nerves innervating the stomach
and the intrinsic gastric nervous system are in constant interaction with the interstitial
cells of Cajal, and thus may modulate relaxation and contraction of gastric smooth
muscle. The regional variation of the relationship between electrical activity and
tension development is the result of a proximal-to-distal gradient in cell resting-
membrane potentials from –48 mV in the fundus to –75 mV in the pylorus.6,9 This
difference is likely related to differences in the density of calcium-dependent potas-
sium channels, since a chemical voltage clamp involving different concentrations of
potassium chloride can change both the resting-membrane potential and the tonic
contraction of smooth muscle obtained from different regions of the stomach.10 This
Pathophysiology and Management of Diabetic Gastropathy 429
relationship has been suggested to be the electrical basis for contraction and relax-
ation in canine gastric smooth muscle.10 This relationship may aid in understanding
the varying mechanical functions of different gastric compartments, as well as the
propagation of slow waves in an organized fashion from the proximal body to the
pylorus.
In human stomach, gastric pacemakers generate rhythmic depolarizations at a
frequency of three cycles per minute, resulting in circular muscle contractions.6,11
Abnormal rhythms of gastric myoelectrical activity, termed gastric dysrhythmias,
originate from abnormal or ectopic gastric pacemakers. A suggested classification
system includes a definition for tachygastria (> 6 cycles/min), bradygastria (< 3
cycles/min), bradytachyarrythmia, or absent activity.12, 13
III. PATHOPHYSIOLOGY OF DIABETIC GASTROPATHY
In this chapter, we will address the pathophysiology, symptoms, and treatment
options in patients with diabetic gastropathy. Potential pathophysiological abnor-
malities include: gastric dysrrhythmias,14–16 antral hypomotility,17 pylorospasm,18 and
gastroparesis.14,19
There are several potential mechanisms to explain altered gastric physiology in
patients with diabetes mellitus (Table 23.1). Almost 50 percent of diabetic patients
have some form of neuropathy, such as peripheral, autonomic, proximal, or focal
neuropathy, but gastrointestinal symptoms are not seen in all of these patients.20
Although the pathophysiology of diabetic neuropathy has not been clearly deter-
mined, the highest rates of diabetic neuropathy have been seen among patients with
long-standing disease, especially in those patients with poor glycemic control.20,21
Although autonomic dysfunction, particularly vagal neuropathy,17,22–23 has been tra-
ditionally regarded as the likely origin for diabetic gastropathy, morphologic abnor-
malities of the vagus nerve or gastric myenteric plexus in patients with diabetes
mellitus have not been routinely identified using conventional histology.24 Neurop-
athies, such as axonopathy in sympathetic nerves25 and ultrastructural and morpho-
metric changes in parasympathetic nerves,26 have been described in animal models
of diabetes mellitus.27,28 A decrease in the interstitial cells of Cajal, decreased
inhibitory neurotransmitter systems containing neuronal nitric-oxide synthase, vaso-
active intestinal peptide, or tyrosine hydroxylase immunopositive nerve fibers, and
TABLE 23.1Potential Pathophysiologic
Mechanisms for Diabetic
Gastropathy
1. Neuropathy
2. Myopathy
3. Glycemic Control
4. Impaired Antioxidant Capacity
430 Nutrition and Diabetes: Pathophysiology and Management
increased levels of excitatory neurochemical and substance P have been observed
in the gut of long-standing diabetic patients.29 Further research examining the
neuropathic aspects of diabetic gastropathy is needed to better define this potential
pathophysiological feature.
There is a complex relationship between glycemic control and upper-gastrointes-
tinal function. Postprandial glucose levels both determine and are determined by the
delivery rate of nutrients from the stomach to the small intestine. Studies in both
healthy individuals and diabetic individuals have revealed that hyperglycemia can
affect gastrointestinal function (Table 23.2). It has been previously shown that
hyperglycemia can induce: 1) delayed gastric emptying;30–34 2) rapid gastric empty-
ing;35 3) gastric myoelectrical disturbances;36 4) inhibition of migrating motor com-
plexes; 5) inhibition of antral motility;37 6) pyloric contractions;38 7) inhibition of
gallbladder contractions and small-intestinal transit;39,40 8) altered esophageal motil-
ity; and 9) decreased lower esophageal sphincter pressure.41
Normalization of blood-glucose levels in diabetic patients has been shown to
improve gastric-emptying times.33 Previous studies have shown that secretion of the
pancreatic hormone, human Pancreatic Polypeptide (hPP), is regulated by vagal-
nerve input. Hyperglycemia can reduce hPP secretion, as well as gastric secretory
and plasma hPP responses to modified sham feeding in humans; these findings
support the notion of impaired vagal-cholinergic activity during hyperglycemia.42,43
Very low plasma levels of hPP have been reported in diabetic patients with cardiac
autonomic neuropathy and delayed gastric emptying.44 In support of this concept,
patients with poorly controlled diabetes mellitus have an increased perception of
upper-gastrointestinal symptoms, such as nausea, fullness, early satiety, and upper-
abdominal pain.45–47 The exact mechanisms by which hyperglycemia leads to dis-
turbances in gastric motility has not been fully delineated.
Unfortunately, much of the available information on the effects of blood-glucose
concentration on upper-gastrointestinal motor and sensory function has been obser-
vational. Available data on potential mechanisms that may mediate these effects are
sparse. Major neurochemicals involved in the regulation of gastrointestinal motor
TABLE 23.2Effects of Hyperglycemia on Upper
Gastrointestinal Function
1. Delayed Gastric Emptying
2. Accelerated Gastric Emptying
3. Gastric Myoelectrical Disturbances
4. Inhibition of Migrating Motor Complexes
5. Inhibition of Antral Motility
6. Pyloric Contractions
7. Inhibition of Gallbladder Contractions
8. Slowing of Small Intestinal Transit
9. Disturbances of Esophageal Motility
10. Decreased Lower Esophageal Sphincter Tonic Contraction
Pathophysiology and Management of Diabetic Gastropathy 431
function include nitric oxide (NO),48–50 vagally mediated cholinergic input, and vaso-
vagal reflexes.51,52 In animal studies utilizing diabetic rats, there is evidence support-
ing the presence of impaired NO-synthase expression in the gastric myenteric
plexus.53 Delayed gastric emptying can be reversed by restoration of neuronal NO-
synthase expression through addition of insulin or addition of the phosphodiesterase
inhibitor sildenafil, which increases NO signaling.54
As an additional possible mechanism, impaired antioxidant status, which is
associated with accelerated liquid gastric emptying,55 has been noted in individuals
with impaired glucose tolerance and diabetes.56 However, a potential association
with delayed gastric emptying has not yet been delineated.
Defective cholinergic neuromuscular transmission in the myenteric plexus,57
impaired release of vasoactive intestinal polypepetide and calcitonin gene-related
peptide during stimulation of enteric nerves,58 and impaired NO-mediated relaxation
of the duodenum59 have been observed in diabetic rats. Indomethacin, a prostaglan-
din-synthesis inhibitor, reverses gastric dysrhythmia induced by hyperglycemia.60
Additional studies are needed to examine the effects of neurohumoral and cellular
mechanisms, and to elucidate the effects of abnormal glucose homeostasis on gas-
trointestinal motor and sensory function.
Although animal studies provide insight as to the mechanisms of diabetic gas-
tropathy, we should be very careful in extrapolating this information into human
disease. These observations suggest that the effect of glucose homeostasis on the
gastrointestinal system is multifactorial, and more work is required to explore the
pathophysiology of this common problem. In addition to the pathophysiological
effects of glucose homeostasis on gastrointestinal motility, factors that modulate the
rate of gastric emptying must be taken into consideration, such as volume, acidity,
osmolarity, nutrient density, fat content, ileal fat, colonic/rectal distention, and use
of medications.
IV. SYMPTOMS OF DIABETIC GASTROPATHY
Although gastrointestinal symptoms are common among diabetic patients seen in
diabetic clinics,62 the prevalence of most gastrointestinal-tract symptoms is similar
in persons in the community without diabetes mellitus.63 In subspecialty clinics, 76
percent of diabetic patients who participated in a survey had one or more gastrointes-
tinal symptoms (Table 23.3), including constipation, diarrhea, fecal incontinence,
and upper-abdominal symptoms, including nausea and vomiting.62 These patients
are not immune to the presence of functional gastrointestinal symptoms, perhaps
leading to an overestimation of symptom prevalence.
V. PERSPECTIVES ON EVALUATION OF GASTRIC EMPTYING
Beaumont made the earliest comments on the rates of gastric emptying in the early
19th century during his observations utilizing a patient with a traumatic gastric
fistula.63 Von Luebe performed the first definitive gastric-emptying study by a single
432 Nutrition and Diabetes: Pathophysiology and Management
gastric aspiration seven hours after liquid-meal ingestion.64 Rehfuss introduced
repeated sampling of gastric contents at regular intervals.65 Hunt and Spurrell used
an aspiration technique to measure the volume of a residual test solution and the
concentration of a marker that was believed to estimate the amount emptied.66
To overcome the need for repeated gastric intubation, George described a method
using double-sampling of the stomach contents.67 A marker was administered fol-
lowing the initial sampling of a test meal. The marker concentration in the subsequent
sampling allowed calculation of the remaining gastric volume, and the chloride
concentration of the sample enabled determination of the rate of gastric secretion.
Recovery of a gastric marker from the duodenum, with the help of duodenal and
gastric intubation through a triple lumen assembly, allowed measurement of gastric
emptying. In addition, distal-duodenal sampling allowed measurement of pancreatic
and biliary secretions.68
The first gastric x-ray studies concentrated on gastric motility rather than eval-
uation of gastric-emptying time.69,70 Subsequent x-ray contrast studies examined the
emptying of liquid barium sulfate or a radiopaque meal. With these techniques, only
complete gastric-emptying time of radiopaque material could be calculated, because
the volume and density of gastric residual barium could not be determined radio-
graphically. Dissociation of barium into liquid phase allowed assessment of only
liquid emptying in tests using solid meals impregnated with barium granules.71
Comparison of a barium test meal with scintigraphic gastric emptying did not reveal
a correlation between the magnitude of retained barium at six hours and the half-
time, as well as percentage of gastric isotope remaining at six hours after ingestion
of a test meal.72 Therefore, results from these two tests are not comparable.
VI. CONTEMPORARY METHODS FOR EVALUATION OF GASTRIC EMPTYING
The presence of multiple methods to evaluate gastric emptying is an indication of
the absence of a precise and widely available technique (namely, a gold standard).
Different techniques have limitations that need to be overcome. The following
section critically analyzes and summarizes contemporary methods used for the
assessment of gastric emptying of solids.
TABLE 23.3Clinical Presentation
for Patients with
Diabetic Gastropathy
1. Abdominal Pain
2. Nausea
3. Emesis
4. Abdominal Bloating
5. Diarrhea
6. Constipation
Pathophysiology and Management of Diabetic Gastropathy 433
A. UPPER-GASTROINTESTINAL X-RAY SERIES
Since radiocontrast material is not a physiological meal and residual gastric barium
can not be quantitatively measured, unless there is significant prolongation of gastric
emptying, an upper-gastrointestinal X-ray series is not sufficiently sensitive to com-
ment on gastric emptying. The primary role of these X-ray studies is to exclude a
significant mucosal abnormality or a gastric-outlet obstruction.
B. SCINTIGRAPHIC ASSESSMENT OF GASTRIC EMPTYING
This test is sensitive, quantitative, noninvasive, easy to perform, and a physiologic
method. Therefore, this test is currently considered to be the gold standard for the
assessment of gastric emptying in research and clinical practice. The technique is
based on the measurement of the disappearance of a radioisotope from the gastric
region during scintigraphic scanning. Evaluation of gastric emptying of solids is a
more sensitive technique, since gastric emptying of liquids is usually preserved even
in the presence of abnormal solid gastric emptying. Gastric emptying of liquids can
be clinically useful if the presence of rapid gastric emptying, termed dumping
syndrome, is suspected.
There are important, basic points that alter the sensitivity and specificity of
scintigraphic gastric-emptying studies.73 First, radioisotope marker should effec-
tively bind to substrate, be nonabsorbable, be resistant to a wide range of pH, and
be stable during the procedure. All studies should contain the same meal volume,
composition, and caloric content. A standard patient position should be preserved
to prevent variations due to the effect of posture. Appropriate corrections for radio-
isotope decay, three-dimensional motion of intragastric material, penetration, atten-
uation, and scattering must also be considered.
The use of a variety of radioisotopes, meals, and separate protocols by individual
hospital centers impede the comparison of gastric-emptying studies from different
institutions. Most major centers use either technetium99-labeled scrambled egg or
chicken liver. Simplified standardized scintigraphic gastric-emptying protocols have
been studied in order to establish normal gastric-emptying values, as well as to
screen patients with suspected gastric dysmotility.74,75 In these studies, one-half
emptying time of a gastric radioisotope (t1/2) is a commonly assessed parameter.
Unfortunately, scintigraphic gastric-emptying studies do not provide information
with regards to the etiology and pathophysiology of gastric dysmotility. There is
frequently no direct correlation between gastric-emptying time, patient symptoms,
and their response to therapy.76
C. TRACER METHODS
These methods are based on the assumption that measurement of the appearance of
a marker substance either in the blood or in expired air can serve as an indirect
estimation of gastric emptying. Gastric emptying should be the rate-limiting step in
the appearance of a marker substance either in the blood or in expired air. Specifi-
cally, the amount of gastric content that enters the duodenum should directly correlate
with the amount that is absorbed and appeared in the blood or expired air. It is
434 Nutrition and Diabetes: Pathophysiology and Management
assumed that the absorption, transport, and metabolism of a marker are constant
both interindividually and intraindividually. Mucosal diseases that alter absorption,
pancreatic diseases, hepatic diseases, and pulmonary diseases, as well as hemody-
namic variations, can alter the accuracy of these studies.
Paracetamol,77 C13-octanoic acid,78–82 and C13-acetate have been used as markers
in these tracer studies.83 In contrast to scintigraphic studies, the absence of ionizing
radiation in C13 breath tests enables the safe evaluation of children and pregnant
women. Tracer methods can be used in centers without gamma camera, in physician’s
offices, or at a patient’s hospital bedside. These tests are considered as test choice
in certain centers in Europe, but are not widely used at this time in the U.S.
D. ULTRASONOGRAPHY
Real-time ultrasonographic evaluation of gastric emptying is based upon the mea-
surement of changes in the cross-sectional area of the antrum in response to a test
meal.84–86 The return of antral area and volume to the fasting baseline are considered
to mark the final emptying time. Gastric-contraction frequency can also be measured
by ultrasonography.87 Ultrasonography has been suggested to be equivalent to and
a valid alternative to the use of scintigraphy.88,89 The main advantages of this method
are that it is noninvasive, widely available, and there is absence of ionizing radiation.
This makes ultrasonography suitable for repeated examinations. However, it is time-
consuming, operator dependent, and difficult to perform in obese patients. It is also
difficult to perform this test in the presence of excessive abdominal gas, it generally
measures liquid gastric emptying, and it is not suitable for patients following partial
gastrectomy.
E. MAGNETIC RESONANCE IMAGING (MRI)
This noninvasive, radiation-free technique is very promising for providing informa-
tion on gastric emptying, anatomical morphology, and gastric secretion.90,91 Improve-
ments in MRI technology could allow the study of gastric motility.92,93 The cost and
availability of MRI presently limit its clinical utility.
F. ELECTROGASTROGRAPHY (EGG)
EGG is a noninvasive method for the recording of gastric myoelectrical activity by
placing electrodes on the anterior abdominal wall.95 The correlation between the
cutaneous EGG recordings and myoelectrical activity recorded from gastric serosal
electrodes has been previously validated.96–98 Important parameters that can be
obtained with the use of EGG include different frequency components and relative
power change.99 Normal gastric slow-wave frequency is considered to range between
two and four cycles per minute. Conditions below this range are termed bradygastria,
and above this range are termed tachygastria, or, as a general term, gastric arrhyth-
mia. The relative power change corresponds to the gastric-contractile strength. Since
gastric myoelectric activity is only one of many factors that alter gastric emptying,
the correlation between EGG and gastric emptying is variable.100–103 According to a
recent expert consensus opinion, the positive predictive value of an abnormal EGG
Pathophysiology and Management of Diabetic Gastropathy 435
to predict delayed gastric emptying averages 65 percent, while the accuracy of a
normal EGG to predict normal gastric emptying averages 75 percent.104 Gastric
dysrhythmias rather than gastric retension may be a better prognosticator of upper-
gastrointestinal symptoms.105 Therefore, EGG may be a complementary study rather
than a replacement for standard gastric-emptying studies. Further studies are needed
to clarify the potential role for and indications for performance of EGG.
VII. EVALUATION OF PATIENTS WITH SUSPECTED DIABETIC GASTROPATHY
Suggestions for the potential evaluation of patients with suspected diabetic gastrop-
athy are outlined in Figure 23.1.
Major historical features can include a history of long-standing, insulin-dependent
diabetes mellitus or a prior history of peptic-ulcer disease. The patient may have known
diabetic nephropathy or diabetic retinopathy, which could support a diagnosis of gut
autonomic neuropathy. A history of migraine headaches could support the presence
of cyclical-vomiting syndrome. Suggestive gastrointestinal symptoms of diabetic gas-
tropathy may include nausea, emesis, weight loss, history of dehydration, or early
satiety. It is quite important to try to elicit the potential use of medications that can
alter gastric emptying, including use of over-the-counter, nonsteroidal, antiinflamma-
tory drugs or antihistamines, or prescription narcotics or anticholinergic compounds,
such as antispasmotics. Nonsteroidal, antiinflammatory drug use may be detected by
a serum platelet aggregation assay. Use of narcotics may be detected by urine screening.
In young individuals, bulimia must be considered.
FIGURE 23.1 Suggested evaluation of suspected diabetic gastropathya. Modified from sug-
gestions of Hasler, WL and Chey, WD, Gastroenterology, 125, 1860, 2003.
History and PhysicalExamination
Laboratory Tests (CBC, TSH,Electrolytes), Abdominal X-Ray
Upper Endoscopy+/–
Upper GI-Small Intestinal X-Ray
Mechanical Obstruction
Treatment
No Obstruction
Scintigraphy,Electrogastrography
Abnormal
Prokinetics, Antiemetics,Dietary Modification
Normal
Consider Etiologies,Symptomatic
Treatment
436 Nutrition and Diabetes: Pathophysiology and Management
On physical examination, potential evidence for a peripheral neuropathy (stock-
ing, glove) should be sought. Examination of the extremities includes looking for
evidence of sclerodactyly. Upon examination of the abdomen, percussion in the
upper abdomen or shaking the upper abdomen may confirm the presence of a
succussion splash. It can be helpful to perform auscultation of the abdomen during
percussion of the upper abdomen, which is designed to elicit a splashing sound due
to the presence of air and fluid in the stomach. Normally, less than 200 ml of fluid
is present in the stomach following an overnight fast.
Laboratory testing should include examination for potential thyroid dysfunction,
hypokalemia, chronic renal failure, or hypercalcemia. Upper endoscopy is preferred
in order to exclude ulcer disease or an obstruction at the pylorus or proximal
duodenum. In the absence of obstruction, solid-meal gastric-emptying studies by
scintigraphy are more readily available to look for evidence of delayed gastric
emptying.
VIII. TREATMENT STRATEGIES IN DIABETIC GASTROPATHY
A. INTRODUCTION
The medical management of diabetic gastric disorders is challenging and may
become frustrating for both clinicians and their patients. Present management prin-
ciples include dietary and supportive care, optimizing care of an underlying etiology,
and symptomatic relief. Medicines that alter gastrointestinal motility, such as anti-
cholinergic medications and opiate agonists, should be avoided. Patients who do not
respond to dietary and lifestyle modifications, improved glycemic control, and phar-
macologic agents may be candidates for endoscopic or surgical intervention for
symptomatic and supportive management.
B. DIETARY AND SUPPORTIVE THERAPY
Dietary modifications, such as use of low-residue, low-lipid, high-liquid-content
meals in small but frequent portions may decrease bezoar formation, improve symp-
toms and prevent malnutrition, dehydration, and electrolyte imbalances. Some
patients may benefit from a gastroparesis diet.106 Enteral feeding can permit adequate
nutritional support and hydration in those patients who do not tolerate oral intake.
Parenteral nutrition is reserved for patients in whom enteral feeding is not possible.
C. OPTIMIZING GLYCEMIC CONTROL
Hyperglycemia may cause antral hypomotility and pyloric contractions,107 affect gastric
motility,108 and impair the efficacy of prokinetic agents.109,110 Gastric-emptying disor-
ders may result in erratic glycemic control due to variability of glucose availability or
absorption. Optimizing glycemic control may improve gastric dysmotility and patient
symptoms. It is not presently clear whether improved nutrition alters patient symptoms
via a mechanism that could include increased tissue levels of antioxidants.
Pathophysiology and Management of Diabetic Gastropathy 437
D. METOCLOPRAMIDE
Metoclopromide, the only Food and Drug Administration-approved agent for the
treatment of gastroparesis, has both prokinetic and antiemetic effects through its
antidopaminergic, 5-HT3 antagonist, and 5-HT4 agonist properties.106 Its prokinetic
effects are limited to the upper-gastrointestinal tract. The usual oral dose ranges
from 5 mg to 20 mg before meals and at bedtime, and is best provided in syrup
form if gastroparesis is suspected. It can also be given to patients intravenously or
subcutaneously if there is intolerance to oral intake. Although metoclopramide
provides symptomatic relief and accelerates gastric emptying,111–113 its prokinetic
effects are not sustained over a long period of time.114 It appears that its symptomatic
relief may be due to its central antiemetic properties rather than being related to its
prokinetic effects. Contrary to early studies, a more recent publication did not show
any symptomatic, prokinetic benefit over use of a placebo.115
Numerous adverse events affect up to 20 percent of patients, including devel-
opment of acute dystonic reactions, extrapyramidal effects, drowsiness, fatigue,
lassitude, restlessness, akathisia, irritability, elevation of serum prolactin level, Par-
kinson-like symptom profile, and tardive dyskinesia (which may be irreversible after
the discontinuation of the drug).113,116–118 The poor side-effect profile and inconsistent
efficacy on gastric emptying may limit the long-term use of metoclopramide in
patients with diabetic gastropathy and gastric retention.
E. ERYTHROMYCIN
Erythromycin is a macrolide antibiotic that has prokinetic properties through its
presumed activation of motilin receptors.119 This agent may increase the amplitude
and frequency of antral contractions, as well as initiation of gastric phase three
contractions of the migrating motor complex.120–121 There is a motilin-receptor gra-
dient in mammalian gastrointestinal tract, with the highest concentrations identified
in the upper-gastrointestinal tract.122 Administration of erythromycin has been
reported to improve solid and liquid gastric emptying in diabetic, postvagotomy, and
idiopathic gastroparesis.123–127 Intravenous doses in acute treatment range between
1 to 3 mg/kg every eight hours. The commonly used oral doses are between 50 to
250 mg/kg every six to eight hours. Although the optimal dosing and route of
administration has not yet been resolved, oral regimen does not appear to be as
effective as intravenous administration.128 Unfortunately, the long-term efficacy of
erythromycin has been unsatisfactory and may include the risks of long-term anti-
biotic use.129 Adverse events induced by erythromycin include abdominal pain,
cramping, nausea, and vomiting.
F. CISAPRIDE
Cisapride, a prokinetic agent with a mixed 5-HT3 antagonist and 5-HT4 agonist
activity, has been extensively evaluated in those patients with gastrointestinal dys-
motility and gastroesophageal-reflux disease. Its effects on gastric emptying are
likely due to stimulation and coordination of antral-pyloro-duodenal motility and
possibly due to changes in gastric-outlet resistance.130–135 Although cisparide has
438 Nutrition and Diabetes: Pathophysiology and Management
been shown to accelerate gastric emptying in multiple studies, the correlation
between improved gastric emptying and control of patient symptoms has remained
less convincing.136–139 Reports of arrythmias and sudden death related to prolongation
of the QT interval resulted in significant restrictions on the routine use of cisapride
in the United States.140–142 Most of these adverse events occurred in the context of
concomitant systemic diseases or drugs that could prolong cisapride metabolism.
G. DOMPERIDONE
Domperidone, similar to metoclopromide, is an agent with both prokinetic and
antiemetic properties related to its peripheral dopamine 2 receptor antagonist activ-
ity; this agent blocks dopamine’s inhibitory effects on smooth muscle.143 Domperi-
done is not available routinely in the United States, but it is available in Canada. Its
antiemetic property is due to its antidopaminergic action on the central chemore-
ceptor trigger zone. Unlike metoclopromide, this agent does not cross the
blood–brain barrier; therefore, adverse central nervous system side effects are less
likely.144,145 Domperidone has been shown to improve liquid and solid gastric
emptying and symptoms during the acute treatment of patients with diabetic gastro-
paresis.144,146 The long-term treatment effects on gastric emptying and symptoms
have been variable.146–148 Side effects of domperidone are related to elevated serum
prolactin levels, headache, diarrhea, somnolence, and abdominal pain.143
H. TEGASEROD
Tegaserod is a serotonergic (5-HT4) receptor partial agonist and has been approved
by the FDA for treatment of women with constipation-predominant irritable-bowel
syndrome.149 Although it increases orocecal transit time with preliminary promising
results on gastric emptying, further studies are needed to determine its role in the
management of gastroparesis.150–152 Use of tegaserod has been associated in routine
medical care with the development of diarrhea, and possibly ischemic colitis.
I. REFRACTORY GASTROPATHY
Some patients with refractory diabetic gastropathy undergo repeated hospitalizations
for dehydration, develop protein-calorie malnutrition, or require frequent outpatient
encounters. Frequent hospitalizations and outpatient encounters for refractory nausea,
vomiting, and dehydration can be major burdens to health-care costs, as well as to the
patient’s quality of life. Acceptable management of these difficult problems in refrac-
tory patients has been developed in medical centers that utilize a team approach.
Management decisions can include input from an endocrinologist, a gastroenterologist,
a nutritionist, a therapeutic radiologist, and a gastrointestinal surgeon.
Therapeutic options that utilize pharmacologic agents are limited for the treat-
ment of refractory gastroparesis. Surgically or endoscopically placed gastro-jejunal
or jejunal feeding tubes provide nutrition and rehydration by using a defined formula
diet or elemental diet, and permit delivery of medications in a patient with a poorly
emptying stomach. A gastrostomy or jejunostomy port allows simultaneous decom-
pression of a dilated stomach or small intestine.153,154 Unfortunately, it is extremely
Pathophysiology and Management of Diabetic Gastropathy 439
difficult and time-consuming to maintain gastrojejunostomy tubes that have been
placed by therapeutic endoscopy. These devices are best managed in specialized
centers that have extensive experience in their utilization and limitations. The use
of total parenteral nutrition can be considered, especially in those patients with a
generalized gastrointestinal motility disorder. Total parenteral nutrition should be
reserved for those individuals who have not responded clinically during the use of
an elemental diet. Data on the long-term effects of parenteral and enteral nutrition
and micronutrients on diabetic gastroparesis is lacking.
Early data appears promising in specialty centers that have studied an external-
stimulation device with temporary electrodes to pace the stomach.155–157 These stud-
ies have shown improvement in symptoms and gastric emptying. Although these
devices are available in the United States, further controlled trials are needed to
define their role in the management of refractory diabetic gastroparesis.
Select patients with refractory diabetic gastroparesis have been referred to sur-
gery for total gastrectomy and formation of an esophago-jejunostomy. This extensive
procedure should be reserved for those medical centers in which there is experience
in the complex preoperative and postoperative evaluation and management of these
patients.
IX. FUTURE STUDIES
Diabetes mellitus is a common medical problem that can result in gastrointestinal
dysmotility secondary to acute hyperglycemic changes or chronic changes resulting
in neuropathic or myopathic disorders. The most common presenting symptoms of
patients with diabetic gastroparesis are nausea, vomiting, bloating, early satiety,
postprandial fullness, and upper-abdominal discomfort and pain. Available clinical
treatments are often unsatisfactory for refractory patients. Future research goals
could include studies of micronutrient supplementation or studies of improved gly-
cemic control by pancreas or islet-cell transplantation. It will be important to assess
their effects on clinical symptoms, gastric emptying, and myopathic and neuropathic
changes in the gut.
REFERENCES
1. Soykan, I, Sivri, B, Sarosiek, I, Kiernan, B, and McCallum, RW, Demography, clinical
characteristics, psychological and abuse profiles, treatment, and long-term follow-up
of patients with gastroparesis, Dig. Dis. Sci., 43(11), 2398, 1998.
2. Hoogerwerf, WA, Pasricha, PJ, Kalloo, AN, and Schuster, MM, Pain: The overlooked
symptom in gastroparesis, Am. J. Gastroenterol., 94(4), 1029, 1999.
3. Sarna, SK, In vivo myoelectrical activity: methods, analysis, and interpretation, in
Handbook of Physiology: The Gastrointestinal System, Vol. 1, Shultz, SG, Wood, JD,
and Rauner, BB, Eds., Oxford University Press, New York, 1989, chap. 21.
4. Sanders, KM and Publicover, NG, Electrophysiology of the gastric musculature, in
Handbook of Physiology: The Gastrointestinal System, Vol. 1, Shultz, SG, Wood, JD,
and Rauner, BB, Eds., Oxford University Press, New York, 1989, chap. 5.
440 Nutrition and Diabetes: Pathophysiology and Management
5. Thuneberg, L, Interstitial cells of Cajal, in Handbook of Physiology: The Gastrointes-
tinal System, Vol. 1, Shultz, SG, Wood, JD, and Rauner, BB, Eds., Oxford University
Press, New York, 1989, chap. 10.
6. Szurszewski, JH, Electrophysiological basis of gastrointestinal motility, in Physiology
of the Gastrointestinal Tract, Vol. 1, Johnson, LR, Christensen, J, Jackson, MJ,
Jacobson, ED, and Walsh, JH, Eds., Raven Press, New York, 1987, chap. 12.
7. Hanani, M and Freund, HR, Interstitial cells of Cajal — their role in pacing and
signal transmission in the digestive system, Acta. Physiol. Scand., 170, 177, 2000.
8. Horowitz, B, Ward, SM and Sanders, KM, Cellular and molecular basis for electrical
rhythmicity in gastrointestinal muscles, Ann. Rev. Physiol., 61, 19, 1999.
9. El-Sharkawy, TY, Morgan, KG, and Szurszewski, JH, Intracellular electrical activity
of canine and human gastric smooth muscle, J. Physiol., 279, 291, 1978.
10. Morgan, KG, Muir, TC, and Szurszewski, JH, The electrical basis for contraction
and relaxation in canine fundal smooth muscle, J. Physiol., 311, 475, 1981.
11. Hinder, RA and Kelly, KA, Human gastric pacesetter potential: Site of origin, spread,
and response to gastric transection and of proximal vagotomy, Am. J. Surg., 133, 29,
1997.
12. Koch, KL and Stern, RM, Electrogastrography, in Illustrated Guide to Gastrointesti-
nal Motility, Kumar, D and Wingate, D, Eds., Churchhill Livingstone, London, 1993,
290.
13. Chen, JDZ and McCallum, RW, Clinical applications of electrogastrography, Am. J.
Gastroenterol., 88, 1324, 1993.
14. Koch, KL, Stern, RM, Stewart, WR, and Vasey, MW, Gastric emptying and gastric
myoelectrical activity in patients with diabetic gastroparesis: Effect of long-term
domperidone treatment, Am. J. Gastroenterol., 84, 1069, 1989.
15. Rothstein, RD, Alavi, A, and Reynolds, JC, Electrogastrography in patients with
gastroparesis and effect of long-term cisapride, Dig. Dis. Sci., 38, 1518, 1993.
16. Koch, KL, Electrogastrography: Physiological basis and clinical application in dia-
betic gastropathy, Diabet. Tech. Ther., 3, 51, 2001.
17. Malagelada, JR, Rees, WD, Mazzotta, LJ, and Go, VLW, Gastric motor abnormalities
in diabetic and postvagotomy gastroparesis: Effect of metoclopramide and
bethanechol, Gastroenterology, 78, 286, 1980.
18. Mearin, FO, Camilleri, M, and Malagelada, JR, Pyloric dysfunction in diabetics with
recurrent nausea and vomiting, Gastroenterology, 90, 1919, 1986.
19. Quigley, EMM, Gastric motor and sensory function, and motor disorders of the
stomach, in Sleissenger and Fordtran’s Gastrointestinal and Liver Disease, Feldman,
M, Friedman, LS, and Sleisenger, MH, Eds., WB Saunders, Philadelphia, 2002, 691.
20. http://diabetes.niddk.nih.gov/dm/pubs/neuropathies.
21. Fedele, D and Giugliano, D, Peripheral diabetic neuropathy. Current recommenda-
tions and future prospects for its prevention and management, Drugs, 54, 414, 1997.
22. Camilleri, M and Malagelada, JR, Abnormal intestinal motility in diabetics with the
gastroparesis syndrome, Eur. J. Clin. Invest., 14, 420, 1984.
23. Dooley, CP, el Newihi, HM, Zeidler, A, and Valenzuela, JE, Abnormalities of the
migrating motor complex in diabetics with autonomic neuropathy and diarrhea,
Scand. J. Gastroenterol., 23, 217, 1988.
24. Yoshida, MM, Schuffler, MD, and Sumi, SM, There are no morphologic abnormalities
of the gastric wall or abdominal vagus in patients with diabetic gastroparesis, Gas-
troenterology, 94, 907, 1988.
25. Yagihashi, S and Sima, AA, Diabetic autonomic neuropathy in the BB rat. Ultrastruc-
tural and morphometric changes in sympathetic nerves, Diabetes, 34, 558, 1985.
Pathophysiology and Management of Diabetic Gastropathy 441
26. Yagihashi, S and Sima, AA, Diabetic autonomic neuropathy in BB rat. Ultrastructural
and morphometric changes in parasympathetic nerves, Diabetes, 35, 733, 1986.
27. Monckton, G and Pehowich, E, Autonomic neuropathy in the streptozotocin diabetic
rat, Can. J. Neurol. Sci., 7, 135, 1980.
28. Zhang, WX, Chakrabarti, S, Greene, DA, and Sima, AA, Diabetic autonomic neur-
opathy in BB rats and effect of ARI treatment on heart-rate variability and vagus
nerve structure, Diabetes, 39, 613, 1990.
29. He, CL, Soffer, EE, Ferris, CD, Walsh, RM, Szurszewski, JH, and Farrugia G, Loss
of interstitial cells of Cajal and inhibitory innervation in insulin-dependent diabetes,
Gastroenterology, 121, 427, 2001.
30. Aylett, P, Gastric emptying and change of blood glucose level, as affected by glucagon
and insulin, Clin. Sci., 22, 171, 1962.
31. MacGregor, IL, Gueller, R, Watts, HD, and Meyer, JH, The effect of acute hypergly-
cemia on gastric emptying in man, Gastroenterology, 70, 190, 1976.
32. Schvarcz, E, Palmer, M, Aman, J, Horowitz, M, Stridsberg, M, and Berne C, Phys-
iological hyperglycemia slows gastric emptying in normal subjects and patients with
insulin-dependent diabetes mellitus, Gastroenterology, 113, 60, 1997.
33. Fraser, RJ, Horowitz, M, Maddox, AF, Harding, PE, Chatterton, BE, and Dent, J,
Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mel-
litus, Diabetologia, 33, 675, 1990.
34. Samsom, M, Akkermans, LM, Jebbink, RJ, van Isselt, H, Vanberge-Henegouwen,
GP, and Smout, AJ, Gastrointestinal motor mechanisms in hyperglycaemia induced
delayed gastric emptying in type I diabetes mellitus, Gut, 40, 641, 1997.
35. Nowak, TV, Johnson, CP, Kalbfleisch, JH, Roza, AM, Wood, CM, Weisbruch, JP, and
Soergel, KH, Highly variable gastric emptying in patients with insulin dependent
diabetes mellitus, Gut, 37, 23, 1995.
36. Jebbink, RJ, Samsom, M, Bruijs, PP, Bravenboer, B, Akkermans, LM, Vanberge-
Henegouwen, GP, and Smout, AJ, Hyperglycemia induces abnormalities of gastric
myoelectrical activity in patients with type I diabetes mellitus, Gastroenterology, 107,
1390, 1994.
37. Barnett, JL and Owyang, C, Serum glucose concentration as a modulator of interdi-
gestive gastric motility, Gastroenterology, 94, 739, 1988.
38. Fraser, R, Horowitz, M, and Dent, J, Hyperglycaemia stimulates pyloric motility in
normal subjects, Gut, 32, 475, 1991.
39. De Boer, SY, Masclee, AA, Lam, WF, Schipper, J, Jansen, JB, and Lamers, CB,
Hyperglycemia modulates gallbladder motility and small intestinal transit time in
man, Dig. Dis. Sci., 38, 2228, 1993.
40. De Boer, SY, Masclee, AA, Lam, WF, Lemkes, HH, Schipper, J, Frohlich, M, Jansen,
JB, and Lamers, CB, Effect of hyperglycaemia on gallbladder motility in type 1
(insulin-dependent) diabetes mellitus, Diabetologia, 37, 75, 1994.
41. De Boer, SY, Masclee, AA, Lam, WF, and Lamers, CB, Effect of acute hyperglycemia
on esophageal motility and lower esophageal sphincter pressure in humans, Gastro-
enterology, 103, 775, 1992.
42. Lam, WF, Masclee, AA, de Boer, SY, and Lamers, CB, Hyperglycaemia reduces
gastrin-stimulated gastric acid secretion in humans, Eur. J. Clin. Invest., 28, 826, 1998.
43. Lam, WF, Masclee, AA, de Boer, SY, and Lamers, CB, Hyperglycemia reduces gastric
secretory and plasma pancreatic polypeptide responses to modified sham feeding in
humans, Digestion, 54, 48, 1993.
442 Nutrition and Diabetes: Pathophysiology and Management
44. Loba, JM, Saryusz-Wolska, M, Czupryniak, L, and Kukulski, K, Pancreatic polypep-
tide secretion in diabetic patients with delayed gastric emptying and autonomic
neuropathy, J. Diabetes Complic., 11, 328, 1997.
45. Schvarcz, E, Palmer, M, Ingberg, CM, Aman, J, and Berne, C, Increased prevalence
of upper gastrointestinal symptoms in long-term type 1 diabetes mellitus, Diabet.
Med., 13, 478, 1996.
46. Bytzer, P, Talley, NJ, Leemon, M, Young, LJ, Jones, MP, and Horowitz, M, Gas-
trointestinal symptoms in diabetes are associated with diabetic complications but not
with current glycemic control, Gastroenterology, 118, A468, 2000.
47. Samsom, M, Salet, GA, Roelofs, JM, Akkermans, LM, Vanberge-Henegouwen, GP,
and Smout, AJ, Compliance of the proximal stomach and dyspeptic symptoms in
patients with type I diabetes mellitus, Dig. Dis. Sci., 40, 2037, 1995.
48. Desai, KMW, Sessa, WC, and Vane, JR, Involvement of nitric oxide in the reflex
relaxation of the stomach to accommodate food or fluid, Nature, 351, 477, 1991.
49. Coulie, B, Tack, J, Sifrim, D, Andrioli, A, and Janssens, J, Role of nitric oxide in
fasting gastric fundus tone and in 5-HT1 receptor-mediated relaxation of the fundus,
Am. J. Physiol., 276, G373, 1999.
50. Russo, A, Fraser, R, Adachi, K, Horowitz, M, and Boeckxstaens, G, Evidence that
nitric oxide mechanisms regulate small intestinal motility in humans, Gut, 44, 72,
1999.
51. Azpiroz, F and Malagelada, JR, Importance of vagal input in maintaining gastric tone
in the dog, J. Physiol., 384, 511, 1987.
52. Jahnberg, T, Gastric adaptive relaxation: effects of vagal activation and vagotomy:
An experimental study in dogs and man, Scand. J. Gastroenterol., 46, 1, 1977.
53. Takahashi, T, Nakamura, K, Itoh, H, Sima, AA, and Owyang C, Impaired expression
of nitric oxide synthase in the gastric myenteric plexus of spontaneously diabetic
rats, Gastroenterology, 113, 1535, 1997.
54. Watkins, CC, Sawa, A, Jaffrey, S, Blackshaw, S, Barrow, RK, Snyder, SH, and Ferris,
CD, Insulin restores neuronal nitric oxide synthase expression and function that is
lost in diabetic gastropathy, J. Clin. Invest., 106, 373, 2000.
55. Koch, TR, Yuan, LX, Petro, A, and Opara, EC, Effects of omeprazole and ascorbate
on gastric emptying and antioxidant levels in a mouse model of glutathione depletion,
Dig. Dis. Sci., 47, 2486, 2002.
56. Vijayalingam, S, Parthiban, A, Shanmugasundaram, KR, and Mohan, V, Abnormal
antioxidant status in impaired glucose tolerance and non-insulin-dependent diabetes
mellitus, Diabet. Med., 13, 715, 1996.
57. Nowak, TV, Harrington, B, Kalbfleisch, JH, and Amatruda, JM, Evidence for abnor-
mal cholinergic neuromuscular transmission in diabetic rat small intestine, Gastro-
enterology, 91, 124, 1986.
58. Belai, A, Lincoln, J, and Burnstock, G, Lack of release of vasoactive intestinal
polypeptide and calcitonin gene-related peptide during electrical stimulation of
enteric nerves in streptozotocin-diabetic rats, Gastroenterology, 93, 1034, 1987.
59. Martinez-Cuesta, MA, Massuda, H, Whittle, BJ, and Moncada, S, Impairment of
nitrergic-mediated relaxation of rat isolated duodenum by experimental diabetes, Br.
J. Pharmacol., 114, 919, 1995.
60. Hasler, WL, Soudah, HC, Dulai, G, and Owyang, C, Mediation of hyperglycemia-
evoked gastric slow-wave dysrhythmias by endogenous prostaglandins, Gastroenter-
ology, 108, 727, 1995.
61. Feldman, M and Schiller, LR, Disorders of gastrointestinal motility associated with
diabetes mellitus, Ann. Intern. Med., 98, 378, 1983.
Pathophysiology and Management of Diabetic Gastropathy 443
62. Maleki, D, Locke, GR, III, Camilleri, M, Zinsmeister, AR, Yawn, BP, Leibson, C,
and Melton, LJ, Gastrointestinal tract symptoms among persons with diabetes mellitus
in the community, Arch. Int. Med., 160, 2808, 2000.
63. Beaumont, W, Experiments and observations of the gastric juice and physiology of
digestion, Allen Plattsburgh, 1833.
64. Leube, W, Beitrage zur diagnostik der magenkrankheiten, Dtsch. Arch. Klin. Med.,
33, 1, 1883.
65. Rehfuss, M, Diagnosis and Treatment of Diseases of the Stomach, WB Saunders,
Philadelphia, 1927.
66. Hunt, JN and Spurrell, WR, The pattern of emptying of the human stomach, J. Phys.,
113, 157, 1951.
67. George, JD, A new clinical method for measuring the role of gastric emptying: The
double sampling test meal, Gut, 9, 237, 1968.
68. Meeroff, J, Go, VLW, and Phillips, S, Gastric emptying of liquids in man: Quantifi-
cation by duodenal recovery marker, Mayo Clin. Proc., 48, 728, 1973.
69. Cannon, WB, The movement of intestines studied by means of roentgen rays, Am.
J. Phys., 6, 250, 1902.
70. Kastle, C, Reider, H, and Rosenthal, J, The bioroentgenography of the internal organs,
Arch. Roentgen. Ray., 15, 3, 1910.
71. Horton, R, Ross, F, and Darling, G, Determination of the gastric emptying time of
the stomach by the use of enteric coated barium granules, Brit. Med. J., 1, 1537, 1965.
72. Perkel, MS, Fajman, WA, Hersh, T, Moore, C, Davidson, ED, and Haun, C, Com-
parison of the barium test meal and the gamma camera scanning technic in measuring
gastric emptying, Southern Med. J., 74, 1065, 1981.
73. Christian, PE, Datz, FL, Sorenson, JA, and Taylor, A, Technical factors in gastric
emptying studies, J. Nucl. Med., 24, 264, 1983.
74. Tougas, G, et al., Assessment of gastric emptying using a low fat meal: Establishment
of international control values, Am. J. Gastroenterol., 95, 1456, 2000.
75. Thomforde, GM, et al., Evaluation of an inexpensive screening scintigraphic test of
gastric emptying, J. Nucl. Med., 36, 93, 1995.
76. Corinaldesi, R, et al., Effect of chronic administration of cisapride on gastric emptying
of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis,
Gut, 28, 300, 1987.
77. Willems, M, Quartero, AO, and Numans, ME, How useful is paracetamol absorption
as a marker of gastric emptying? A systematic literature study, Dig. Dis. Sci., 46,
2256, 2001.
78. Ghoos, YF, et al., Measurement of gastric emptying rate of solids by means of a
carbon-labeled octanoic acid breath test, Gastroenterology, 104, 1640, 1993.
79. Choi, MG, et. al., Reproducibility and simplification of 13C-octanoic acid breath test
for gastric emptying of solids, Am. J. Gastroenterol., 93, 92, 1998.
80. Choi, MG, et al., [13C]octanoic acid breath test for gastric emptying of solids:
Accuracy, reproducibility, and comparison with scintigraphy, Gastroenterology, 112,
1155, 1997.
81. Maes, BD, et al., [13C]Octanoic acid breath test to measure gastric emptying rate of
solids, Dig. Dis. Sci., 39(12 Suppl.), 104S, 1994.
82. Ziegler, D, et al., [13C]Octanoic acid breath test for non-invasive assessment of gastric
emptying in diabetic patients: Validation and relationship to gastric symptoms and
cardiovascular autonomic function, Diabetologia, 39, 823, 1996.
83. Mossi, S, et al., Gastric emptying of liquid meals measured noninvasively in humans
with [13C]acetate breath test, Dig. Dis. Sci., 39(12 Suppl.), 107S, 1994.
444 Nutrition and Diabetes: Pathophysiology and Management
84. Bateman, DN and Whittingham, TA, Measurement of gastric emptying by real-time
ultrasound, Gut, 23, 524, 1982.
85. Holt, S, Cervantes, J, Wilkinson, AA, and Wallace, JHK, Measurement of gastric
emptying rate in humans by real-time ultrasound, Gastroenterology, 90, 918, 1986.
86. Bolondi, L, et al., Measurement of gastric emptying time by real-time ultrasonogra-
phy, Gastroenterology, 89, 752, 1985.
87. Holt, S, et al., Dynamic imaging of the stomach by real-time ultrasound — a method
for the study of gastric motility, Gut, 21, 597, 1980.
88. Benini, L, et al., Simultaneous measurement of gastric emptying of a solid meal by
ultrasound and by scintigraphy, Am. J. Gastroenterol., 94, 2861, 1999.
89. Holt, S, Cervantes, J, Wilkinson, AA, and Wallace, JH, Measurement of gastric
emptying rate in humans by real-time ultrasound, Gastroenterology, 90, 918, 1986.
90. Schwizer, W, Maecke, H, and Fried, M, Measurement of gastric emptying by magnetic
resonance imaging in humans, Gastroenterology, 103, 369, 1992.
91. Finle, C, et al., Scintigraphic validation of MRI method to study gastric emptying of
a solid meal in humans, Gut, 44, 106, 1999.
92. Sicca, GT, MR imaging for assessment of gastric motility disorders: Has its time
come? Radiology, 207, 9, 1998.
93. Kunz, P, et al., Gastric emptying and motility: assessment with MR imaging —
preliminary observations, Radiology, 207, 33, 1998.
94. Younes, Z, Regan, F, and Schuster, MM, Functional MRI for the assessment of gastric
motility — a better test? Am. J. Gastroenterol., 94, 851, 1999.
95. Chen, JD and McCallum, RW, Clinical applications of electrogastrography, Am. J.
Gastroenterol., 88, 1324, 1993.
96. Hamilton, JW, et al., Human electrogastrograms — comparison of surface and
mucosal recordings, Dig. Dis. Sci., 31, 33, 1986.
97. Familoni, BO, Bowes, KL, Kingma, YJ, and Cote, KR, Can transcutaneous recordings
detect gastric electrical abnormalities? Gut, 32, 141, 1991.
98. Lin, Z, Chen, JDZ, Schirmer, BD, and McCallum, RW, Postprandial response of
gastric slow waves: Correlation of serosal recordings with the electrogastrogram,
Dig. Dis. Sci., 45, 645, 2000.
99. Chen, JD and McCallum, RW, Clinical applications of electrogastrography, Am. J.
Gastroenterol., 88, 1324, 1993.
100. Koch, KL, Stern, RM, Stewart, WR, and Vasey, MW, Gastric emptying and gastric
myoelectrical activity in patients with diabetic gastroparesis: Effect of long-term
domperidone treatment, Am. J. Gastroenterol., 84, 1069, 1989.
101. Lin, Z, Eaker, E., Sarosiek, I, and McCallum, RW, Gastric myoelectrical activity and
gastric emptying in patients with functional dyspepsia, Am. J. Gastroenterol., 94,
2384, 1999.
102. Chen, JCZ, Lin, Z, Pan, J and McCallum, RW, Abnormal gastric myoelectrical
activity and delayed gastric emptying in patients with symptoms suggestive of gas-
troparesis, Dig. Dis. Sci., 41, 1538, 1996.
103. Geldoff, H, der Schee, EJ, van Blankenstein, M, and Grashuis, HL, Electrogastro-
graphic study of gastric myoelectrical activity in patients with unexplained nausea
and vomiting, Gut, 27, 799, 1986.
104. Parkman, HP, Hasler, WL, Barnett, JL, Eaker, EY, and American Motility Society
Clinical GI Motility Testing Task Force, Electrogastrography: A document prepared
by the gastric section of the American Motility Society Clinical GI Motility Testing
Task Force, Neurogastroenterol. Motil., 15, 89, 2003.
Pathophysiology and Management of Diabetic Gastropathy 445
105. Parkman, HP and Fisher, RS, Disorders of gastric emptying, in Textbook of Gastro-
enterology, Vol. 1, Yamada, T, Alpers, DH, Kaplowitz, N, Laine, L, Owyang, C, and
Powell, DW, Eds., Lippincott, Williams, & Wilkins, Philadelphia, 1292, 2003.
106. Koch, KL, Diabetic gastropathy: Gastric neuromuscular dysfunction in diabetes mel-
litus: a review of symptoms, pathophysiology, and treatment, Dig. Dis. Sci., 44, 1061,
1999.
107. Fraser, R, Horowitz, M, and Dent, J, Hyperglycaemia stimulates pyloric motility
in normal subjects, Gut, 32, 475, 1991.
108. Barnett, JL and Owyang, C, Serum glucose concentration as a modulator of interdi-
gestive gastric motility, Gastroenterology, 94, 739, 1988.
109. Jones, KL, et al., Hyperglycemia attenuates the gastrokinetic effect of erythromycin
and affects the perception of postprandial hunger in normal subjects, Diabet. Care,
22, 339, 1999.
110. Petrakis, IE, et al., Hyperglycemia attenuates erythromycin-induced acceleration of
liquid-phase gastric emptying of hypertonic liquids in healthy subjects, Dig. Dis. Sci.,
47, 67, 2002.
111. Snape, WJ, Jr. et al., Metoclopramide to treat gastroparesis due to diabetes mellitus:
A double-blind, controlled trial, Ann. Int. Med., 96, 444, 1982.
112. Perkel, MS, Moore, C, Hersh, T, and Davidson, E.D., Metoclopramide therapy in
patients with delayed gastric emptying: a randomized, double-blind study, Dig. Dis.
Sci., 24, 662, 1979.
113. Minami, H and McCallum, RW, The physiology and pathophysiology of gastric
emptying in humans, Gastroenterology, 86, 1592, 1984.
114. Schade, RR, et al., Effect of metoclopramide on gastric liquid emptying in patients
with diabetic gastroparesis, Dig. Dis. Sci., 30, 10, 1985.
115. McHugh, S, Lico, S, and Diamant, NE, Cisapride vs metoclopramide. An acute study
in diabetic gastroparesis, Dig. Dis. Sci., 37, 997, 1992.
116. Ganzini, L, Casey, DE, Hoffman, WF, and McCall, AL, The prevalence of metoclo-
pramide-induced tardive dyskinesia and acute extrapyramidal movement disorders,
Arch. Int. Med., 153, 1469, 1993.
117. Miller, LG and Jankovic, J, Metoclopramide-induced movement disorders. Clinical
findings with a review of the literature, Arch. Int. Med., 149, 2486, 1989.
118. Albibi, R and McCallum, RW, Metoclopramide: Pharmacology and clinical applica-
tion, Ann. Int. Med., 98, 86, 1983.
119. Peeters, T, et al., Erythromycin is a motilin receptor agonist, Am. J. Phys., 257,
G470, 1989.
120. Chen, JD, Lin, ZY, Edmunds, MC, III, and McCallum, RW, Effects of octreotide and
erythromycin on gastric myoelectrical and motor activities in patients with gastro-
paresis, Dig. Dis. Sci., 43, 80, 1998.
121. Tack, J, et al., Effect of erythromycin on gastric motility in controls and in diabetic
gastroparesis, Gastroenterology, 103, 72, 1992.
122. Koutsoviti-Papadopoulou, M, Kounenis, G, and Elezoglou, V, Effect of erythromycin
on different parts of the rabbit intestine: Comparison with motilin, Gen. Pharmacol.,
25, 93, 1994.
123. Janssens, J, et al., Improvement of gastric emptying in diabetic gastroparesis by
erythromycin. Preliminary studies, N. Engl. J. Med., 322, 1028, 1990.
124. Urbain, JL, et al., Intravenous erythromycin dramatically accelerates gastric emptying
in gastroparesis diabeticorum and normals and abolishes the emptying discrimination
between solids and liquids, J. Nucl. Med., 31, 1490, 1990.
446 Nutrition and Diabetes: Pathophysiology and Management
125. Richards, RD, Davenport, K, and McCallum, RW, The treatment of idiopathic and
diabetic gastroparesis with acute intravenous and chronic oral erythromycin, Am. J.
Gastroenterol., 88, 203, 1993.
126. Mozwecz, H, et al., Erythromycin stearate as prokinetic agent in postvagotomy
gastroparesis, Dig. Dis. Sci., 35, 902, 1990.
127. Stacher, G, et al., Erythromycin effects on gastric emptying, antral motility and
plasma motilin and pancreatic polypeptide concentrations in anorexia nervosa, Gut,
34, 166, 1993.
128. De Ponti, F and Malagelada, JR, Functional gut disorders: from motility to sensitivity
disorders. A review of current and investigational drugs for their management, Phar-
macol. Ther., 80, 49, 1998.
129. Camilleri, M, The current role of erythromycin in the clinical management of gastric
emptying disorders, Am. J. Gastroenterol., 88, 169, 1993.
130. Fraser, R, Horowitz, M, Maddox, A, and Dent, J, Dual effects of cisapride on gastric
emptying and antropyloroduodenal motility, Am. J. Phys., 264(2 Part 1), G195, 1993.
131. Fraser, RJ, Horowitz, M, Maddox, AF, and Dent, J, Postprandial antropyloroduodenal
motility and gastric emptying in gastroparesis — effects of cisapride, Gut, 35, 172,
1994.
132. De Ponti, F and Malagelada, JR, Functional gut disorders: from motility to sensitivity
disorders. A review of current and investigational drugs for their management, Phar-
macol. Ther., 80, 49, 1998.
133. Borovicka, J, et al., Evaluation of gastric emptying and motility in diabetic gastro-
paresis with magnetic resonance imaging: effects of cisapride, Am. J. Gastroenterol.,
94, 2866, 1999.
134. Edelbroek, M, et al., Effect of cisapride on myoelectrical and motor responses of
antropyloroduodenal region during intraduodenal lipid and antral tachygastria in
conscious dog, Dig. Dis. Sci., 40, 901, 1995.
135. Malbert, CH, Serthelon, JP, and Dent, J, Changes in antroduodenal resistance induced
by cisapride in conscious dogs, Am. J. Phys., 263(2 Part 1), G202, 1992.
136. McCallum, RW, Cisapride: A new class of prokinetic agent, The ACG Committee on
FDA-related matters. American College of Gastroenterology, Am. J. Gastroenterol.,
86, 135, 1991.
137. McHugh, S, Lico, S, and Diamant, NE, Cisapride vs metoclopramide. An acute study
in diabetic gastroparesis, Dig. Dis. Sci., 37, 997, 1992.
138. Camilleri, M, et al., Effect of six weeks of treatment with cisapride in gastroparesis
and intestinal pseudoobstruction, Gastroenterology, 96, 704, 1989.
139. Richards, RD, et al., Objective and subjective results of a randomized, double-blind,
placebo-controlled trial using cisapride to treat gastroparesis, Dig. Dis. Sci., 38, 811,
1993.
140. Bedford, TA and Rowbotham, DJ, Cisapride. Drug interactions of clinical signifi-
cance, Drug Safety, 15, 167, 1996.
141. Vitola, J, Vukanovic, J, and Roden, DM, Cisapride-induced torsades des pointes, J.
Cardiovasc. Electrophys., 9, 1109, 1998.
142. Nightingale, SL, New warnings added to cisapride labeling, JAMA, 280, 410, 1998.
143. Barone, JA, Domperidone: A peripherally acting dopamine2-receptor antagonist, Ann.
Pharmacother., 33, 429, 1999.
144. Patterson, D, Abell, T, Rothstein, R, Koch, K, and Barnett, J, A double-blind multi-
center comparison of domperidone and metoclopramide in the treatment of diabetic
patients with symptoms of gastroparesis, Am. J. Gastroenterol., 94, 1230, 1999.
Pathophysiology and Management of Diabetic Gastropathy 447
145. Brogden, RN, Carmine, AA, Heel, RC, Speight, TM, and Avery, GS, Domperidone.
A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy
in the symptomatic treatment of chronic dyspepsia and as an antiemetic, Drugs, 24,
360, 1982.
146. Horowitz, M., et al., Acute and chronic effects of domperidone on gastric emptying
in diabetic autonomic neuropathy, Dig. Dis. Sci., 30, 1, 1985.
147. Davis, RH, Clench, MH, and Mathias, JR, Effects of domperidone in patients with
chronic unexplained upper gastrointestinal symptoms: A double-blind, placebo-con-
trolled study, Dig. Dis. Sci., 33, 1505, 1988.
148. Soykan, I, Sarosiek, I, and McCallum, RW, The effect of chronic oral domperidone
therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients
with gastroparesis, Am. J. Gastroenterol., 92, 976, 1997.
149. Camilleri, M, Review article: Tegaserod, Aliment. Pharmacol. Ther., 15, 277, 2001.
150. Degen, L, et al., Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric
emptying and gastrointestinal transit in healthy male subjects, Aliment. Pharmacol.
Ther., 15, 1745, 2001.
151. Prather, CM, et al., Tegaserod accelerates orocecal transit in patients with constipa-
tion-predominant irritable bowel syndrome, Gastroenterology, 118, 463, 2000.
152. Tougas, G, et al., Tegaserod improves gastric emptying in patients with gastroparesis
and dyspeptic symptoms, Gastroenterology, 124(Suppl. 1), 432, 2003.
153. Fontana, RJ and Barnett, JL, Jejunostomy tube placement in refractory diabetic
gastroparesis: A retrospective review, Am. J. Gastroenterol., 91, 2174, 1996.
154. Pitt, HA, et al., Chronic intestinal pseudo-obstruction. Management with total
parenteral nutrition and a venting enterostomy, Arch. Surg., 120, 614, 1985.
155. Abell, T, et al., Gastric electrical stimulation for medically refractory gastroparesis,
Gastroenterology, 125, 421, 2003.
156. Forster, J, et al., Further experience with gastric stimulation to treat drug refractory
gastroparesis, Am. J. Surg., 186, 690, 2003.
157. Lin, Z, Forster, J, Sarosiek, I, and McCallum, RW, Treatment of gastroparesis with
electrical stimulation, Dig. Dis. Sci., 48, 837, 2003.